Manumycin A inhibits triple-negative breast cancer growth through LC3-mediated cytoplasmic vacuolation death

P K Singha1, S Pandeswara, M A Venkatachalam

  • 1Department of Pathology, UT Health Science Center at San Antonio, San Antonio, TX 78229, USA.

Cell Death & Disease
|January 19, 2013
PubMed

Insights

Manumycin A induces non-apoptotic cell death in triple-negative breast cancer (TNBC) by causing cytoplasmic vacuolation. This novel therapeutic approach targets cancer cells while sparing normal cells, offering a promising strategy for aggressive TNBC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Therapy resistance in cancer, particularly triple-negative breast cancer (TNBC), is often linked to anti-apoptotic mechanisms.
  • Developing therapeutic strategies that induce non-apoptotic cell death is crucial for overcoming apoptosis resistance in aggressive cancers.

Purpose of the Study:

  • To investigate the effects of manumycin A (Man A), a farnesyl protein transferase inhibitor, on TNBC cell viability and death.
  • To elucidate the mechanism of Man A-induced cell death, focusing on its non-apoptotic and non-autophagic nature.

Main Methods:

  • Treatment of TNBC cells and normal mammary epithelial cells with Man A.
  • Analysis of cell viability, cytoplasmic vacuolation, and expression of key proteins including LC3, p62, ER stress markers (Bip, CHOP), p21, p27, PTEN, and pAkt.
  • In vivo studies using xenograft models to assess Man A's effect on tumor burden.
  • LC3 knockdown experiments in MDA-MB-231 cells.

Main Results:

  • Man A reduced TNBC cell viability by inducing non-apoptotic, non-autophagic cytoplasmic vacuolation death.
  • This process involved endoplasmic reticulum (ER) stress, LC3 and p62 pathways, and accumulation of ubiquitinated proteins, independent of apoptosis and autophagy inhibitors.
  • Man A selectively targeted TNBC cells, sparing normal mammary epithelial cells, and reduced tumor burden in vivo.
  • Man A-induced effects, including tumor growth suppression and modulation of specific protein expressions, were mimicked by LC3 knockdown.

Conclusions:

  • Manumycin A represents a novel therapeutic agent for TNBC, inducing a unique form of cell death characterized by cytoplasmic vacuolation.
  • The mechanism likely involves ER stress and LC3/p62 pathways, with potential targeting of sulfhydryl homeostasis.
  • Man A demonstrates significant therapeutic potential due to its efficacy against TNBC and selectivity over normal cells.